L

Liver Institute Northwest | Seattle, WA

Research site
(Unclaimed)
Location
3216 NE 45th Place, Suite 212, Seattle, Washington, United States of America
Site insights

Top conditions

Non-alcoholic Fatty Liver Disease (15 trials)

Fatty Liver (15 trials)

Cholangitis (11 trials)

Biliary Liver Cirrhosis (6 trials)

Liver Cirrhosis (5 trials)

Top treatments

Cilofexor
Resmetirom
Volixibat
Elafibranor
MGL-3196
Lanifibranor
EDP-305
PLN-74809
Ursodeoxycholic Acid
PF-06865571

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

15 of 29
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )

This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis histological stage F2 or F3

Enrolling
NASH - Nonalcoholic Steatohepatitis
Drug: Placebo
Drug: IVA337

A 52-Week, Multi-center, Open-label, Active Treatment Extension Study to Evaluate Safety and Tolerability of Once Daily, Oral Administration of Resme...

Enrolling
Non-Alcoholic Fatty Liver Disease
Drug: Resmetirom

This study will determine the effect of oral 80 mg resmetirom administered once daily on participants with well-compensated non-alcoholic steatohepat...

Enrolling
NASH
Cirrhosis, Liver
Drug: Resmetirom
Drug: Placebo

A double-blind placebo controlled randomized Phase 3 study to determine if 80 or 100 mg of MGL-3196 as compared with placebo resolves NASH and/or red...

Active, not recruiting
NASH - Nonalcoholic Steatohepatitis
Drug: Placebo
Drug: MGL-3196

This is a safety study to evaluate BOS-580 administered subcutaneously over 12 weeks in Part A or 24 weeks in Part B.

Enrolling
Nonalcoholic Steatohepatitis (NASH)
Drug: BOS-580
Drug: Placebo

This study will evaluate the effects of elafibranor (the study drug) in participants with Primary Sclerosing Cholangitis (PSC). PSC is a rare disease...

Enrolling
Primary Sclerosing Cholangitis
Drug: Elafibranor 80 mg
Drug: Placebo Matched to Elafibranor 80 mg

The purpose of this clinical research study is to learn more about the use of the study medicine, volixibat, for the treatment of pruritus (itching)...

Enrolling
PBC
Primary Biliary Cholangitis
Drug: Volixibat
Drug: Placebo

The purpose of this clinical research study is to learn more about the use of the study medicine, volixibat, for the treatment of pruritus (itching)...

Enrolling
Primary Sclerosing Cholangitis
Drug: Volixibat
Drug: Placebo

This study is being done to see if a combination of 2 medicines (called NNC0194-0499 and semaglutide) can reduce liver damage in patients with non al...

Active, not recruiting
Non-alcoholic Steatohepatitis
Drug: NNC0174 0833 10 mg/mL
Drug: NNC0194 0499 50 mg/mL

An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects with Primary Biliary Cholangitis (PBC)

Enrolling
Primary Biliary Cirrhosis
Drug: Seladelpar 5 mg Capsule
Drug: Seladelpar 10 mg Capsule

To Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients with Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis.

Enrolling
Primary Biliary Cholangitis
Drug: Placebo
Drug: Seladelpar 10 mg

The participants of this study will have confirmed Primary Biliary Cholangitis (PBC) with inadequate response or intolerance to ursodeoxycholic acid...

Active, not recruiting
Primary Biliary Cirrhosis
Drug: Elafibranor 80mg
Drug: Placebo

The goals of this clinical study are to learn more about the study drugs, semaglutide (SEMA) with the fixed-dose combination (FDC) of cilofexor/firso...

Active, not recruiting
Nonalcoholic Steatohepatitis
Drug: PTM CILO/FIR
Drug: Cilofexor (CILO)/Firsocostat (FIR)

This study is a phase 2 study to Evaluate Efficacy, Safety and Tolerability of HM15211 Treatment for 12 Months in Subjects with Biopsy Confirmed NASH

Enrolling
NASH - Nonalcoholic Steatohepatitis
Drug: HM15211
Drug: Placebo of HM15211

A multicenter, randomized, double-blind, placebo-controlled, parallel, Phase 2a clinical trial to evaluate the efficacy and safety of DA 1241 in subj...

Enrolling
NON-ALCOHOLIC STEATOHEPATITIS
Drug: Sitagliptin
Drug: DA-1241 Placebo

Trial sponsors

M

Madrigal Pharmaceuticals (4 trials)

CymaBay Therapeutics logo

CymaBay Therapeutics (3 trials)

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems